{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-014708","form_type":"8-K","ticker":"SNWV","cik":"0001417663","company_name":"SANUWAVE Health, Inc.","filed_at":"2024-03-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.123243+00:00","generated_at":"2026-06-04T09:00:30.064166+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"SANUWAVE reports record Q4 revenue $7.0M (+27% YoY), positive operating income, guides FY2024 50% growth","bullets":["Q4 2023 revenue record $7.0M (+27% vs Q4 2022 $5.5M); operating income $1.0M vs loss $1.5M.","FY2023 revenue $20.4M (+22% from $16.7M); adjusted EBITDA loss $1.2M vs $7.2M, improvement of $6.0M.","UltraMist systems: 211 sold in FY2023; Q4 consumables revenue $3.6M (+21% YoY).","Guidance: Q1 2024 revenue +45-55% vs Q1 2023; FY2024 revenue growth 50% vs FY2023.","Net income Q4 $18.2M (non-cash derivative fair value change); FY2023 net loss $25.8M."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-014708","json":"https://secwatch.observer/filing/0001140361-24-014708.json","markdown":"https://secwatch.observer/filing/0001140361-24-014708.md","text":"https://secwatch.observer/filing/0001140361-24-014708.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1417663/000114036124014708/0001140361-24-014708-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1417663/000114036124014708/ef20024834_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T09:00:30.064166+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"192575323537e3d69c18b9cedff19c92114e3bb0","claim":"SANUWAVE Health, Inc. reported the fourth quarter and fiscal year ended December 31, 2023 results: revenue $7.0 million, net income $18.2 million. Guidance initiated.","evidence_excerpt":"SANUWAVE Announces Record Q4 and FY2023 Revenue Q4 2023 revenues were a record $7.0 million, up 27% from Q4 2022 FY 2023 revenues were a record $20.4 million, up 22% from FY2022 Operating income was $1 million for Q4 2023 compared to an operating loss of $1.5 million for Q4 2022 Company provides guidance for revenue growth of 45-55% for Q1 2024 vs Q1 2023 and initiates annual guidance for FY2024 of 50% revenue growth vs. FY2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1417663/000114036124014708/0001140361-24-014708-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and fiscal year ended December 31, 2023"},{"label":"Revenue","value":"$7.0 million"},{"label":"Net income","value":"$18.2 million"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}